新华时评：让集采药品真正成为人民健康的“守护盾”

Core Points - The 11th batch of national organized drug procurement successfully opened bidding on October 27 in Shanghai, with 55 drugs successfully procured. Over the past seven years, 490 high-quality and affordable essential and life-saving drugs have entered the public's medicine cabinets through centralized procurement [1][2] - The drug procurement policy has effectively reduced prices by squeezing out unreasonable price margins, providing tangible benefits for the public's medical needs. However, ensuring the quality of procured drugs is crucial for them to serve as a "guardian" of public health [1] - The latest procurement emphasizes strict quality requirements throughout the process, focusing on mature "old drugs" that have been in clinical use for many years, while excluding high-risk drugs from the procurement [1] - The procurement rules have introduced stringent quality thresholds, requiring bidding companies to have relevant production experience and for the drugs to pass regulatory compliance checks. Only companies with stable quality and practical production experience can participate in the bidding [1] Industry Regulations - Successful bidding does not guarantee protection for pharmaceutical companies, as regulatory authorities will conduct comprehensive supervision of selected drugs. If quality issues arise during subsequent inspections, the company will lose its selection qualification and be placed on a violation list, prohibiting participation in future procurements for a specified period [2] - Continuous reinforcement of quality supervision throughout the entire lifecycle of drug production, distribution, and use is essential. Pharmaceutical companies must take responsibility for drug quality and safety as a lifeline [2] - A combination of strict process management and dynamic monitoring is necessary to maintain the quality of drugs, ensuring that the benefits of the procurement policy truly reach the public [2]